Sanofi — Director's Dealing 2021

Jul 29, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Icosavax, Inc. (ICVX)
CIK: 0001786255
Period of Report: 2021-07-28

Reporting Person: Sanofi (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock (par value, $0.0001)	$0.00		Common Stock (3003224)		Indirect
Series B-1 Preferred Stock (par value, $0.0001)	$0.00		Common Stock (85278)		Indirect

Footnotes

F1: The shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock are convertible, at any time at the holder's election, to shares of the Issuer's Common Stock, as shown in Column 3, at a ratio of 4.1557-for-1. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A-1 Preferred Stock and Series B-1 Preferred Stock will automatically convert to shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 as shown in Column 3. The Series A-1 Preferred Stock and Series B-1 Preferred Stock have no expiration date.

F2: Sanofi is the beneficial owner of 3,003,224 Shares of Series A-1 Preferred Stock and 85,278 Shares of Series B-1 Preferred Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc.